Invesco Ltd. Kymera Therapeutics, Inc. Transaction History

Invesco Ltd.

$460 Billion
Q2 2024

A detailed history of Invesco Ltd. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 29,834 shares of KYMR stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,834

Previous 113,367 73.68%

Holding current value

$1.45 Million

Previous $4.56 Million 80.47%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$29.85 - $39.42 $2.49 Million - $3.29 Million	-83,533 Reduced 73.68%	29,834 $890,000
Q1 2024 May 14, 2024	BUY	$22.9 - $43.57 $1.95 Million - $3.72 Million	85,278 Added 303.6%	113,367 $4.56 Million
Q4 2023 Feb 12, 2024	SELL	$10.97 - $26.84 $93,661 - $229,159	-8,538 Reduced 23.31%	28,089 $715,000
Q3 2023 Nov 13, 2023	BUY	$13.9 - $23.88 $86,138 - $147,984	6,197 Added 20.36%	36,627 $509,000
Q2 2023 Aug 11, 2023	SELL	$22.4 - $34.92 $3.56 Million - $5.55 Million	-159,056 Reduced 83.94%	30,430 $699,000
Q1 2023 May 12, 2023	BUY	$24.84 - $38.75 $4.37 Million - $6.82 Million	175,993 Added 1304.33%	189,486 $5.61 Million
Q4 2022 Feb 13, 2023	SELL	$19.57 - $30.92 $58 - $92	-3 Reduced 0.02%	13,493 $336,000
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $1,400 - $2,296	-67 Reduced 0.49%	13,496 $294,000
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $25,547 - $76,930	-1,808 Reduced 11.76%	13,563 $267,000
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $5,153 - $9,443	146 Added 0.96%	15,371 $650,000
Q4 2021 Feb 14, 2022	SELL	$49.91 - $65.56 $8,534 - $11,210	-171 Reduced 1.11%	15,225 $967,000
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $293,109 - $408,759	6,132 Added 66.19%	15,396 $904,000
Q2 2021 Aug 17, 2021	BUY	$31.08 - $51.95 $287,925 - $481,264	9,264 New	9,264 $450,000

Others Institutions Holding KYMR

# of Institutions

160

Shares Held

63.1M

Call Options Held

22.6K

Put Options Held

14.4K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.66B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account